Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

  • Showing results for alon david. Your search for Alon Davidy retrieved no results.
1.

Studying the differential efficacy of postsymptom antitoxin treatment in type A versus type B botulism using a rabbit spirometry model.

Torgeman A, Schwartz A, Diamant E, Baruchi T, Dor E, Ben David A, Pass A, Barnea A, Tal A, Rosner A, Rosen O, Zichel R.

Dis Model Mech. 2018 Sep 27;11(9). pii: dmm035089. doi: 10.1242/dmm.035089.

2.

A Novel Rabbit Spirometry Model of Type E Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.

Diamant E, Pass A, Rosen O, Ben David A, Torgeman A, Barnea A, Tal A, Rosner A, Zichel R.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02379-17. doi: 10.1128/AAC.02379-17. Print 2018 Apr.

3.

An in vitro cell-based potency assay for pharmaceutical type A botulinum antitoxins.

Torgeman A, Diamant E, Levin L, David AB, Epstein E, Girshengorn M, Mazor O, Rosenfeld R, Zichel R.

Vaccine. 2017 Dec 19;35(52):7213-7216. doi: 10.1016/j.vaccine.2017.11.015. Epub 2017 Nov 22.

PMID:
29174678
4.

Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody Preparations.

Torgeman A, Ozeri E, Ben David A, Diamant E, Rosen O, Schwartz A, Barnea A, Makovitzki A, Mimran A, Zichel R.

Toxins (Basel). 2017 May 29;9(6). pii: E180. doi: 10.3390/toxins9060180.

5.

Development of an Innovative in Vitro Potency Assay for Anti-Botulinum Antitoxins.

Rosen O, Ozeri E, Barnea A, David AB, Zichel R.

Toxins (Basel). 2016 Sep 24;8(10). pii: E276. doi: 10.3390/toxins8100276.

6.

Early, Real-Time Medical Diagnosis of Botulism by Endopeptidase-Mass Spectrometry.

Rosen O, Feldberg L, Gura S, Brosh-Nissimov T, Guri A, Zimhony O, Shapiro E, Beth-Din A, Stein D, Ozeri E, Barnea A, Turgeman A, Ben David A, Schwartz A, Elhanany E, Diamant E, Yitzhaki S, Zichel R.

Clin Infect Dis. 2015 Dec 15;61(12):e58-61. doi: 10.1093/cid/civ861. Epub 2015 Sep 28.

PMID:
26420800
7.

Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate.

Ben David A, Torgeman A, Barnea A, Zichel R.

Protein Expr Purif. 2015 Jun;110:122-9. doi: 10.1016/j.pep.2015.02.008. Epub 2015 Feb 26.

PMID:
25727047
8.

Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations.

Diamant E, Lachmi BE, Keren A, Barnea A, Marcus H, Cohen S, David AB, Zichel R.

PLoS One. 2014 Jan 27;9(1):e87089. doi: 10.1371/journal.pone.0087089. eCollection 2014.

9.

The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.

Ben David A, Diamant E, Barnea A, Rosen O, Torgeman A, Zichel R.

Clin Vaccine Immunol. 2013 Aug;20(8):1266-73. doi: 10.1128/CVI.00268-13. Epub 2013 Jun 12.

10.

Enzyme-substrate complex structures of a GH39 beta-xylosidase from Geobacillus stearothermophilus.

Czjzek M, Ben David A, Bravman T, Shoham G, Henrissat B, Shoham Y.

J Mol Biol. 2005 Nov 4;353(4):838-46. Epub 2005 Sep 20.

PMID:
16212978

Supplemental Content

Loading ...
Support Center